1
|
Dupoiron D, Brill S, Eeeltink C, Bell D, Barragán B, Petersen G, Eerdekens M, Ryan D, Rakuša M. 1571P Cancer-related neuropathic pain (CRNP) in Europe: Impact of cancer stage on diagnosis and treatment of patients. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
2
|
Affiliation(s)
- M Eerdekens
- CCO Global Medical Affairs, Grünenthal GmbH, Zieglerstrasse 6, 52078, Aachen, Germany.
| | - M Stupar
- Global Drug Safety, Grünenthal GmbH, Zieglerstrasse 6, 52078, Aachen, Germany
| | - L Marcondes
- GRT US Holding, 360 Mt. Kemble Ave. 3rd FL, Ste 3, Morristown, NJ, 07960, USA
| |
Collapse
|
3
|
Deschamps K, Staes F, Eerdekens M, Peerlinck K, Hermans C, Vandesande J, Lobet S. Postural control during a transition task in haemophilic children, adolescents and young adults with haemophilic ankle arthropathy. Haemophilia 2018; 24:667-674. [DOI: 10.1111/hae.13484] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/11/2018] [Indexed: 11/27/2022]
Affiliation(s)
- K. Deschamps
- Department of Rehabilitation Sciences; Musculoskeletal Rehabilitation Research Group; KULeuven; Leuven (Heverlee) Belgium
- Division of Podiatry; Institut D'Enseignement; Supérieur Parnasse Deux-Alice; Sint-Lambrechts-Woluwe Belgium
- Department of Podiatry; Artevelde University College; Ghent Belgium
- Department of Physical Medicine; University Hospitals Leuven; Pellenberg Belgium
| | - F. Staes
- Department of Rehabilitation Sciences; Musculoskeletal Rehabilitation Research Group; KULeuven; Leuven (Heverlee) Belgium
| | - M. Eerdekens
- Department of Physical Medicine; University Hospitals Leuven; Pellenberg Belgium
| | - K. Peerlinck
- Department of Cardiovascular Sciences; Centre for Molecular and Vascular Biology; KULeuven; Leuven Belgium
| | - C. Hermans
- Service d'hématologie; Cliniques Universitaires Saint-Luc; Bruxelles Belgium
| | - J. Vandesande
- Department of Cardiovascular Sciences; Centre for Molecular and Vascular Biology; KULeuven; Leuven Belgium
| | - S. Lobet
- Service d'hématologie; Cliniques Universitaires Saint-Luc; Bruxelles Belgium
- Secteur des Sciences de la Santé; Institut de Recherche Expérimentale et Clinique; Neuromusculoskeletal Lab (NMSK); Université catholique de Louvain; Brussels Belgium
- Service de médecine physique et réadaptation; Cliniques universitaires Saint-Luc; Brussels Belgium
| |
Collapse
|
4
|
Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Dogan C, Etropolski M, Eerdekens M. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. Eur J Pain 2016; 20:1513-8. [PMID: 27062079 PMCID: PMC5071659 DOI: 10.1002/ejp.875] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/02/2016] [Indexed: 12/05/2022]
Abstract
Background A recent randomized‐withdrawal, active‐ and placebo‐controlled, double‐blind phase 3 study showed that tapentadol prolonged release (PR) was effective and well tolerated for managing moderate to severe, chronic malignant tumour‐related pain in patients who were opioid naive or dissatisfied with current treatment (Pain Physician, 2014, 17, 329–343). This post hoc, subgroup analysis evaluated the efficacy and tolerability of tapentadol PR in patients who previously received and were dissatisfied with tramadol for any reason and who had a pain intensity ≥5 (11‐point numerical rating scale) before converting directly to tapentadol PR. Methods In the original study, eligible patients had been randomized (2:1) and titrated to their optimal dose of tapentadol PR (100–250 mg bid) or morphine sulphate‐controlled release (40–100 mg bid) over 2 weeks. The present report focuses on results during the titration period for a subgroup of patients randomized to tapentadol PR after having been on tramadol treatment prior to randomization in the study (n = 129). Results for this subgroup are compared with results for all 338 patients who received tapentadol PR during titration (overall tapentadol PR group). Results Responder rates (responders: completed titration, mean pain intensity <5 [0–10 scale] and ≤20 mg/day rescue medication during last 3 days) were slightly better for the tramadol/tapentadol PR subgroup (69.8% [90/129]) vs. the overall tapentadol PR group (63.9% [214/335]). Tolerability profiles were comparable for both groups. Conclusions Results of this subgroup analysis indicate that patients with cancer pain could safely switch from prior treatment with the weak centrally acting analgesic tramadol directly to the strong centrally acting analgesic tapentadol PR, for an improved analgesic therapy for severe pain. What does this study add? Results of this post hoc analysis show that patients who had received prior tramadol therapy could switch directly to tapentadol PR, with the majority (˜70%) experiencing improved efficacy.
Collapse
Affiliation(s)
- H G Kress
- Department of Special Anesthesia and Pain Therapy, Medical University of Vienna/AKH, Vienna, Austria.
| | - E D Koch
- Grünenthal GmbH, Aachen, Germany
| | | | - A Steup
- Grünenthal GmbH, Aachen, Germany
| | - K Karcher
- Janssen Research & Development, LLC, Raritan, NJ, USA
| | - C Dogan
- Grünenthal GmbH, Aachen, Germany
| | - M Etropolski
- Janssen Research & Development, LLC, Raritan, NJ, USA
| | | |
Collapse
|
5
|
Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2011; 25:685-97. [PMID: 20615933 DOI: 10.1177/0269881110372817] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The safety and tolerability of paliperidone palmitate, an injectable atypical antipsychotic agent, were assessed in a 1-year open-label extension of a double-blind study in patients with schizophrenia. Patients from the double-blind study who experienced a recurrence, remained recurrence free until study end, or who were in the transition, maintenance or double-blind phases and had received at least one injection of paliperidone palmitate when enrollment was stopped, were eligible for the open-label extension. Patients received gluteal injections of paliperidone palmitate once every 4 weeks: starting dose 50 mg eq. followed by 25, 50, 75, or 100 mg eq. flexible dosing. Of the 388 patients enrolled, 288 completed the open-label extension. During the open-label extension, the median (range) duration of exposure to paliperidone palmitate was 338 days (10; 390), and 74% of patients received all 12 open-label injections of paliperidone palmitate. The most frequent (≥ 5% in total group) adverse events were insomnia (7%); worsening of schizophrenia; nasopharyngitis; headache; and weight increase (6% each). Potentially prolactin-related adverse events occurred in 13 (3%) patients, mostly women, and none resulted in study discontinuation. Extrapyramidal treatment-emergent adverse events were reported in 25 (6%) patients; tremor was the most frequently reported (n = 8, 2%). At open-label extension endpoint, investigator-rated redness at the injection site was observed in ≤ 4% of patients in each group. Injection-site pain was rated by investigators as absent in 82-87% of patients. Schizophrenia symptoms measured by Positive and Negative Syndrome Scale and personal and social performance changes improved during the open-label extension.
Collapse
Affiliation(s)
- S Gopal
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey 08560, USA.
| | | | | | | | | | | |
Collapse
|
6
|
Novotny E, Renfroe B, Yardi N, Nordli D, Ness S, Wang S, Weber T, Kurland CL, Yuen E, Eerdekens M, Venkatraman L, Nye JS, Ford L. Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology 2010; 74:714-20. [PMID: 20089937 DOI: 10.1212/wnl.0b013e3181d1cd4c] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To evaluate the efficacy and safety of adjunctive topiramate (sprinkle capsules or oral liquid) in reducing daily rates of partial-onset seizures (POS) in infants with refractory POS. METHODS In this double-blind, placebo-controlled, parallel-group, international study, infants (n = 149) with clinical or EEG evidence of refractory POS were randomly allocated (1:1:1:1) to receive adjunctive topiramate 5, 15, or 25 mg/kg/d or placebo for 20 days. The primary variable was the median percentage reductions in daily POS rate from baseline to final assessment as recorded on a 48-hour video-EEG. RESULTS Of the 149 infants (mean age 12 months) included in the intent-to-treat analysis set, 130 completed the study. Median percentage reduction from baseline in daily POS rate was not significantly different (p = 0.97) between topiramate 25 mg/kg (20.4%) and placebo (13.1%). Lower doses were not formally tested, but nominal p values for comparisons with placebo were not significant (15-mg/kg/d dose: p = 0.97; 5-mg/kg/d dose: p = 0.91). Treatment-emergent fever, diarrhea, vomiting, anorexia, weight decrease, somnolence, and viral infection occurred more frequently (> or = 10% difference) with topiramate than with placebo. CONCLUSION In infants aged 1-24 months, topiramate 5, 15, or 25 mg/kg/d was not effective as adjunctive treatment for refractory partial-onset seizures. No new safety concerns associated with topiramate use were noted. CLASSIFICATION OF EVIDENCE This interventional study provides Class I evidence that topiramate 5, 15, or 25 mg/kg/d compared with placebo does not significantly reduce seizure rates in infants aged 1 month to 2 years with refractory partial-onset seizures.
Collapse
Affiliation(s)
- E Novotny
- University of Washington, Seattle, WA, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Berwaerts J, Cleton A, Herben V, van de Vliet I, Chang I, van Hoek P, Eerdekens M. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 2009; 42:158-63. [PMID: 19585395 DOI: 10.1055/s-0029-1202265] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Co-morbid medical and psychiatric conditions are common in individuals with schizophrenia. As such, selecting antipsychotic medications with a low potential for drug-drug interactions (DDIs) is crucial, as many are extensively metabolized by hepatic cytochrome P450 (CYP) isozymes. METHODS This randomized, crossover study examined the effects of paroxetine (a potent CYP2D6 inhibitor) on the pharmacokinetic parameters of a single dose of the novel antipsychotic agent, paliperidone extended-release tablets (paliperidone ER), in healthy subjects. RESULTS The mean C (max) and AUC of paliperidone were slightly higher and paliperidone clearance was slightly lower following co-administration of paliperidone ER with paroxetine. There was a ratio of geometric treatment means of 116.48% for AUC (infinity) [90% CI: 104.49-129.84]. However, the increase in total exposure to paliperidone was not considered clinically relevant. The incidence of adverse events was lower when subjects received the combination of paliperidone ER and paroxetine compared with paroxetine alone. DISCUSSION Results suggest that no clinically relevant pharmacokinetic interaction occurs when paroxetine and paliperidone ER are co-administered and, therefore, initiation or discontinuation of concomitant treatment with CYP2D6-inhibiting drugs does not appear to warrant an adjustment in paliperidone ER dosage.
Collapse
Affiliation(s)
- J Berwaerts
- Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ 08560, USA.
| | | | | | | | | | | | | |
Collapse
|
8
|
Meltzer H, Hargarter L, Kramer M, Sherr J, Gassmann-Mayer C, Lim P, Bobo W, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled studies (PAL-SCH-303/304/305). Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Vermeir M, Boom S, Naessens I, Talluri K, Eerdekens M, Hargarter L. Absorption; metabolism and excretion of a single oral dose of 14c-paliperidone 1mg in healthy subjects (PAL-053). Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Karlsson P, Hargarter L, Dencker E, Nyberg S, Mannaert E, Boom S, Talluri K, Rossenu S, Eriksson B, Eerdekens M, Farde L. Pharmacokinetics and dopamine d2 and serotonin 5-ht2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115). Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991781] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Kramer M, Hargarter L, Kushner S, Sherr J, Vijapurkar U, Lim P, Eerdekens M. Delaying symptom recurrence in patients with schizophrenia with paliperidone extended-release tablets: an international, randomized, double-blind, placebo-controlled study (PAL-SCH-301). Pharmacopsychiatry 2007. [DOI: 10.1055/s-2007-991776] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
12
|
Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007; 90:147-61. [PMID: 17092691 DOI: 10.1016/j.schres.2006.09.012] [Citation(s) in RCA: 208] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/22/2006] [Revised: 09/14/2006] [Accepted: 09/18/2006] [Indexed: 11/26/2022]
Abstract
BACKGROUND Paliperidone extended-release tablet (paliperidone ER) is an investigational oral psychotropic developed for schizophrenia treatment. It utilizes OROS technology to provide a unique pharmacokinetic profile, eliminating the need for titration and potentially leading to improved tolerability. Furthermore, paliperidone undergoes limited hepatic metabolism. METHODS The efficacy and safety of once-daily paliperidone ER (6 mg, 9 mg and 12 mg) were assessed versus placebo in 628 patients with acute schizophrenia in a 6-week, multicenter, double-blind, randomized, parallel-group study. RESULTS All doses of paliperidone ER demonstrated significant improvement in PANSS score, all PANSS Marder factor scores (p<0.001) and personal and social functioning versus placebo (p<0.001). The PANSS total score also improved significantly in the olanzapine treatment arm. Significantly higher percentages of paliperidone ER patients demonstrated a > or =30% reduction in PANSS total score versus placebo (p<0.001). The incidence of movement disorder-related AEs and rating scales measurements were similar to placebo for the paliperidone ER 6 mg group and higher in the 9 mg and 12 mg groups. In the paliperidone ER groups there were no reports of glucose-related AEs or clinically relevant changes in plasma lipid levels and changes in mean bodyweight<1 kg. CONCLUSION In this study, all doses of paliperidone ER were effective in significantly improving the symptoms of schizophrenia and personal and social functioning and were generally well tolerated. Paliperidone ER offers a distinctive treatment profile and may provide a valuable new treatment option for patients with schizophrenia.
Collapse
Affiliation(s)
- J Kane
- Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York 11004, USA
| | | | | | | | | | | | | |
Collapse
|
13
|
Eerdekens M, Fleischhacker W, Yang X, Beauclair L, Sauret H, Chrzanowski W, Martin S, Gefvert O. Long-term safety of long-acting risperidone microspheres. Eur Psychiatry 2002. [DOI: 10.1016/s0924-9338(02)80826-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
14
|
|
15
|
Eerdekens M. Treatment delivery: a hope for the future. Eur Psychiatry 2002. [DOI: 10.1016/s0924-9338(02)80175-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
16
|
Razavi D, Vandecasteele H, Primo C, Bodo M, Debrier F, Verbist H, Pethica D, Eerdekens M, Kaufman L. Maintaining abstinence from cigarette smoking: effectiveness of group counselling and factors predicting outcome. Eur J Cancer 1999; 35:1238-47. [PMID: 10615236 DOI: 10.1016/s0959-8049(99)00110-0] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The aim of the study was to assess the effectiveness of worksite group counselling interventions designed to prevent smoking relapse after abstinence has been achieved following 3 months therapy using group support and/or transdermal nicotine replacement therapy. After 3 months, abstinent subjects were randomly allocated either to a counselling group led by professional psychologists (PG), to a counselling group led by former smokers (SG) or to no intervention group (NG). The 3 and 12 months abstinence were defined, respectively, as a sustained smoking cessation during the last month, and the last 9 months. Complete abstinence was confirmed by expired carbon monoxide and by urine cotinine concentrations. The abstinence rate at 3 months was 35.1%. After 12 months abstinence rates were not statistically different in the PG, the SG and the NG (respectively 57.8, 53.4 and 49.6% of those randomised). In multivariate analyzes, baseline variables associated with 12 months abstinence were non-smoking family, gender (male), lower daily intake of nicotine and better psychological adjustment. Mean weight gain at 3 months in abstinent versus relapsed subjects, was respectively, 4.1 and 2.4 kg. Baseline variables associated with weight gain at 3 months were higher Fagerström score, gender (male) and professional status (blue collar worker). Group support after abstinence has been achieved did not significantly improve the abstinence. This study shows the difficulty of preventing smoking relapse with monthly group counselling. The results indicate the need to investigate further specific programmes focusing on factors such as gender, family, nicotine dependence, psychological and weight concerns/issues which may precipitate relapse.
Collapse
Affiliation(s)
- D Razavi
- Université Libre de Bruxelles, Belgium.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
De Deyn PP, Mol L, de Ridder-Vanderdeelen P, Eerdekens M. An open multicentre prospective study of the effects of monotherapy with controlled-release carbamazepine on newly diagnosed generalized tonic-clonic seizures. Seizure 1994; 3:235-8. [PMID: 8000719 DOI: 10.1016/s1059-1311(05)80194-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
In a prospective study, 139 patients who presented newly diagnosed primarily generalized tonic-clonic seizures (GTCS) were treated with monotherapy controlled-release carbamazepine (CR-CBZ) (TegretolCR) during one year. Ninety-three patients completed the trial. Patients were assessed for seizure control and tolerance. Mean number of seizures in the year before entry into the trial was 2.42 +/- 1.69, during one year follow-up this number was 0.77 +/- 2.44 (n = 93). Total number of patients remaining seizure-free during 12 months was 72 out of 93 patients completing the trial. Overall efficacy and tolerance was rated by the investigators as excellent in the majority of patients (respectively 86% and 77%). The results suggest that TegretolCR might be a drug of choice for first line treatment of tonic-clonic seizures given the excellent efficacy and relative lack of toxicity.
Collapse
Affiliation(s)
- P P De Deyn
- Laboratory of Neurochemistry and Behaviour, Born-Bunge Foundation, Wilrijk, Belgium
| | | | | | | |
Collapse
|